SALL2 and breast carcinoma: Furthermore, ipatasertib (GDC‐0068), an Akt inhibitor currently used in clinical breast cancer therapy (Lin et al, 2013; Kim et al, 2017), was used to examine the crucial effect of Akt/mTOR signaling pathway on SALL2 downregulation‐induced tumorigenicity of ER+ breast cancer cells.